Literature DB >> 9392055

Expression of immunohistochemical markers (PCNA, Ki-67, 486p and p53) on paraffin sections and their relation to the recurrence rate of superficial bladder tumors.

R Vorreuther1, R Hake, P Borchmann, S Lukowsky, J Thiele, U Engelmann.   

Abstract

We present a retrospective study using four different immunohistochemical markers (PCNA, Ki-67, 486p and p53) on paraffin sections from 104 selected cases with primary superficial transitional cell carcinomas of the bladder (59 cases pTa, 45 cases pT1, 40 cases G1, 64 cases G2). 53 of the 104 patients experienced recurrence of their bladder lesion, while 51 remained free of tumor. The distribution of staging, grading and multifocality was comparable in both groups of patients. Overall, the tumors that recurred had a significantly higher proportion of labeled cells for PCNA (p < or = 0.0001), Ki-67 (p < or = 0.006) and 486p (p < or = 0.0001). The latter antigen proved to be the most reliable marker. A less significant difference in staining pattern was found for p53 (p < or = 0.01). Evaluating the predictive value of the various antibodies separately for the groups with G1 vs. G2 carcinomas and pTa vs. pT1 tumors revealed a lower significance for all antibodies. The technique of immunostaining on paraffin sections facilitates further retrospective studies on archival material. These markers may provide additional information about the probability of recurrence of superficial bladder tumors. But at the moment they should only be utilized in selected cases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9392055     DOI: 10.1159/000283032

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  5 in total

1.  AgNOR/P53 expression compared with different grades in bladder carcinoma.

Authors:  M Karakök; A Aydin; K Bakir; R Uçak; C Korkmaz
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

2.  The prognostic value of proliferating cell nuclear antigen, Ki-67 and nucleolar organizer region in transitional cell carcinoma of the bladder.

Authors:  Murat Bozlu; Diclehan Orhan; Sümer Baltaci; Onder Yaman; Atilla Halil Elhan; Ozden Tulunay; Yusuf Ziya Müftüoğlu
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 3.  Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example.

Authors:  Peggy Sekula; Julia B Pressler; Willi Sauerbrei; Peter J Goebell; Bernd J Schmitz-Dräger
Journal:  BMJ Open       Date:  2016-08-16       Impact factor: 2.692

4.  Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways.

Authors:  Zuhua Chen; Zhentao Liu; Wenwen Huang; Zhongwu Li; Jianling Zou; Jingyuan Wang; Xiaoting Lin; Beifang Li; Dongshao Chen; Yanting Hu; Jiafu Ji; Jing Gao; Lin Shen
Journal:  J Transl Med       Date:  2017-12-13       Impact factor: 5.531

5.  Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance.

Authors:  Zhentao Liu; Zuhua Chen; Jingyuan Wang; Mengqi Zhang; Zhongwu Li; Shubin Wang; Bin Dong; Cheng Zhang; Jing Gao; Lin Shen
Journal:  J Hematol Oncol       Date:  2018-08-29       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.